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Concomitant presentation of lung dominant anti-PL-7 positive anti-synthetase syndrome in 
association with high risk myelodysplastic syndrome 
Dr Andrew Creamer, Respiratory Registrar 
A seventy-year-old retired teacher was referred to the respiratory clinic with a 12-month history of 
progressive exertional dyspnoea and dry cough. He denied haemoptysis, constitutional symptoms or 
diurnal variation. He took omeprazole, amlodipine and ezetimibe for a longstanding history of 
dyspepsia, hypertension and hypercholesterolaemia. He was an ex-smoker with a 30-pack year 
history.  
He reported monophasic colour change in his fingers in the cold, but denied any other connective 
tissue disease (CTD) symptoms. He denied any significant environmental exposures such as organic 
dusts or moulds.  
Vital signs were normal. There was evidence of mechanic’s hands (a hyperkeratotic eruption with 
fissuring and cracking on the palmar and radial aspect of the fingers, strongly associated with 
idiopathic inflammatory myopathies) but no other features of CTD or clubbing. Bibasal fine 
inspiratory crepitations were audible on chest auscultation.  Cardiovascular examination was 
normal.  
Initial investigations revealed a pancytopenia (Figure 1) with unremarkable liver and renal function, 
prompting referral to local haematology services for further assessment.  
Lung function testing revealed a restrictive pattern with significantly reduced gas transfer (Figure 2), 
whilst 6-minute walk test demonstrated baseline saturations of 95% on air dropping to 77% on 
exertion, achieving 260m (48% of theoretical distance).  
Chest x-ray showed prominent interstitial lung markings in the mid- and lower zones (Figure 3). High-
Resolution CT Thorax (HRCT) demonstrated centrilobular emphysema throughout the lungs and a 
basally predominant interstitial process with features suggestive of non-specific interstitial 
pneumonia (NSIP) (Figure 4). Transthoracic echocardiogram showed preserved LV systolic function 
with mild concentric hypertrophy, normal RV size and function. There was no tricuspid regurgitation 
so an estimate of the pulmonary artery pressure could not be made.  
Dr Shaney L Barratt, Respiratory Consultant 
The differential diagnosis for interstitial lung disease (ILD) presenting in a 70-year old is broad and 
includes hypersensitivity pneumonitis, drug-induced ILD, CTD-ILD and the idiopathic interstitial 
pneumonias, particularly idiopathic pulmonary fibrosis.  There was no history of pneumotoxic 
medication, and no relevant occupational exposures. The radiological pattern and absence of 
relevant exposures made hypersensitivity pneumonitis less likely. The presence of mechanics’ hands 
in a patient with an NSIP pattern suggests the possibility of an underlying connective tissue disease 
and an autoimmune screen is an important part of the initial assessment of new ILD patients. 
The combination of pancytopenia with ILD should prompt consideration of a short telomere 
syndrome, particularly if there is a family history of pulmonary fibrosis or bone marrow failure. 
These are a heterogenous group of inherited disorders of variable penetrance caused by mutations 
that interfere with the normal maintenance of telomeres. However, the patients’ age, absence of 
family history and lack of typical skin or systemic features would not support this. 
Given the wide differential and thorough diagnostic work-up required, a multidisciplinary team 
(MDT) diagnosis taking into consideration clinical, radiological, histopathological and serological 
features is essential.  
AC 
Indirect immunofluorescence using HEp-2 cells demonstrated a cytoplasmic speckled pattern with 
no nuclear staining (anti-nuclear antibody negative / anti-cytoplasmic antibody positive). 
Subsequent myositis spectrum antibody immunoblot testing confirmed anti-PL-7 antibodies (Figure 
5). 
In the context of his clinical features and anti-PL-7 positivity, a diagnosis of lung dominant anti-
synthetase syndrome (ASyS) was made. The patient was commenced on prednisolone 20mg once 
daily, with co-trimoxazole prophylaxis against opportunistic infection and referred for assessment 
for ambulatory oxygen therapy, pending haematological review.  
Dr Rachel Protheroe, Haematology Consultant 
Bone marrow biopsy demonstrated dysplastic megakaryocytes and erythrocytes, reduced 
granulopoiesis and myeloid blasts (6%), consistent with a diagnosis of myelodysplastic syndrome 
(MDS) with excess blasts. 
Myelodysplastic syndromes are clonal haematopoietic stem cell disorders characterized by 
dysplastic, ineffective haematopoiesis associated with progression to acute myeloid leukaemia 
(AML). Treatment is indicated according to the International Prognostic Scoring System (IPSS)1; in 
this case, intermediate-2 risk. Such higher risk MDS carry a major risk of transformation to AML and 
in fit patients can be treated with intensive chemotherapy consolidated with allogeneic stem cell 
transplantation, but the severity of the ILD precluded this.  He was therefore treated with 
azacitidine, a hypomethylating agent.  
There is a recognised association between MDS and autoimmune phenomena (AIP), with a variety of 
serological and clinical syndromes of autoimmunity reported in patients with MDS. Given the 
temporal relationship between the development of MDS and ASyS-associated ILD, it was felt that the 
two may be linked.  
AC 
After 5 cycles of azacitabine a good response in the peripheral blood count was seen (Hb 88, WCC 
1.52, Platelets 227). Unfortunately, lung function continued to deteriorate (Figure 2) with worsening 
dyspnoea. HRCT showed progression of the ground glass component of the ILD (Figure 4). 
Mycophenolate Mofetil 500mg once daily was commenced, but had to be stopped after 4 doses due 
to fall in neutrophils to 0.17 x 109/L. A further trial of prednisolone at a higher dose of 30mg was 
started without significant benefit. In view of the progressive disease despite maximum tolerable 
immunosuppresive therapy, a pathway of low dose prednisolone, alongside best supportive care 
was adopted.   
 
AC, HG, HP, SB 
We present a case of ASyS-associated ILD with a synchronous diagnosis of MDS; the simultaneous 
presentation suggesting a causative relationship. To the authors’ knowledge, this is the first 
described case of ASyS developing in MDS, and of a CTD-ILD associated with MDS.  
ASyS is a distinct subset of autoimmune connective tissue disease , which is historically described 
within the idiopathic inflammatory myopathy spectrum2. It is characterised by the presence of 
autoantibodies against one of several cytoplasmic aminoacyl transfer RNA (tRNA) synthetase 
enzymes2. It is most frequently associated with anti-Jo-1, although seven other autoantibodies, 
including anti-PL-7, have been identified3. Clinical presentation may phenotypically overlap with 
dermatomyositis (DM) or polymyositis (PM) but ASyS can exist in an amyopathic form4. Other clinical 
features include inflammatory arthritis, myositis, mechanics’ hands, fever, and Raynaud’s. 
Associated ILD is common, with lung involvement present in 50-90% cases depending on the auto-
antibody expressed5. In published studies of anti-PL-7 associated ASyS, pulmonary involvement 
occured in 66-100%3,6. The most common pattern of lung involvement is NSIP, with organising 
pneumonia (OP) occurring in a minority of cases6. 
Management of ASyS-associated ILD involves pharmacological and non-pharmacological measures. 
As in other chronic respiratory conditions, oxygen therapy, vaccination and smoking cessation 
should be addressed. Pulmonary rehabilitation should be encouraged for patients with myositis-
associated ILD; studies have demonstrated that physical exercise is safe in myositis and improves 
muscle strength7, although rehabilitation programmes should be delayed if there is evidence of 
active muscle inflammation. Immunomodulatory agents form the mainstay of pharmacological 
treatment of ASyS-ILD. No specific guidelines exist, and the approach should be tailored to the 
acuteness and severity of the initial presentation. A proposed algorithm was published recently8, 
which suggested that in patients with stable mild-moderate disease, oral prednisolone should be 
started alongside a steroid-sparing agent (Mycofenolate Mofetil or azathioprine). If there is 
improvement or stabilisation, the steroid can be weaned down. In patients presenting acutely or in 
respiratory compromise, high dose steroids (typically pulsed intravenous methylprednisolone) 
should be started in combination with cyclosporin or a calcineurin inhibitor. Rituximab, an anti-CD20 
monoclonal antibody, has been used in refractory cases with some success9. The proposal suggests 
that in treatment failure, a trial of intravenous immunoglobulin or referral for transplantation is 
considered.   
 
There is a recognised association between MDS and autoimmune phenomena (AIP). A recent large-
scale multi-centre study of 1,408 patients with MDS found evidence of an autoimmune process in 
28%10, in keeping with previous studies. In this cohort, the presence of AIPs was associated with 
improved overall survival (60 months vs 45 months), and a lower chance of transformation to acute 
leukaemia (23% vs 30%). A wide range of autoimmune phenomena have been reported in MDS, with 
systemic conditions such as Sjogrens syndrome, systemic lupus erythematosis and systemic 
vasculitides all described. Serological evidence of autoimmunity is also frequently identified11. The 
underlying pathogenic mechanisms are unknown, although deranged cytokine production, as well as 
more specific changes in T-cell responses to antigen presentation and abnormal B-cell and T-cell 
interactions have been proposed. In published series, immunosuppressive therapy has improved the 
AIP and haematological indices in a proportion of cases, but this effect is not consistent12.  
A distinct association between ILD and MDS has also been described. In a cohort study of 827 MDS 
patients, 2% had ILD, a rate significantly higher than that of the general population13. In this study, 
only one of the 18 patients with ILD had a CTD diagnosis (rheumatoid arthritis), and none had 
received a hypomethylating agent prior to diagnosis of ILD. Telomere dysfunction was proposed as a 
potential shared mechanism but further research is required to elucidate the exact pathophysiology. 
This case describes a lung-dominant ASyS developing in the context of MDS, presenting with ILD and 
bone marrow failure. An important alternative diagnosis to consider in the combination of bone 
marrow failure and lung fibrosis is telomere-related disease. Telomeres are highly conserved 5’-
TTAGGG-3’ repeats at the ends of chromosomes that confer protection during cellular replication. At 
a molecular level, telomere dysfunction triggers a DNA damage response cascade, that results in 
cellular senescence and apoptosis that may be cell- or tissue-type- specific. The clinical 
manifestations of telomere-mediated disease are thus diverse, although the triad of bone marrow 
failure, liver cirrhosis and idiopathic pulmonary fibrosis is considered to be highly predictive of 
germline telomere mutation14. Six telomere-related genes have been linked to the development of 
familial pulmonary fibrosis, although TERT (Telomerase reverse transcriptase) mutations are most 
frequent, occurring in approximately 15% of those with affected kindreds15. If suspected, telomere 
length analysis or genetic analysis of telomerase-related genes (TERT, TERC, DKC1,TINF2, PARN and 
RTEL1) could be performed.  
 
This case raises several important points for clinicians. ILD is a feature of many CTDs, and as in this 
amyopathic presentation, the classic musculocutaneous features of the condition may be subtle or 
absent. New ILD presentations should therefore prompt a thorough evaluation for symptoms and 
signs of a CTD. As a minimum we suggest this should include a detailed history exploring arthralgia, 
myalgia, skin changes and presence of Raynaud’s or sicca symptoms, with careful examination of the 
hands for subtle clinical signs of mechanic hands, fingertip ulceration, rugged cuticles, dilated 
nailfold capillaries, finger tapering , Gottron’s papules and heliotrope rashes of the face, posterior 
neck and shoulders (shawl sign) or of the anterior neck and chest (V-sign). A basic laboratory screen 
of ANA, rheumatoid factor, anti-CCP (cyclic citrullinated peptide) and creatinine kinase (CK) is 
recommended. In context of suspected anti-synthetase syndrome, a negative ANA screen does not 
necessarily indicate autoantibody negativity; the presence of cytoplasmic staining using cell 
immunofluorescence would be characteristic. We suggest full immunoblot for myositis specific 
antibodies (Anti: Jo-1, PL-12, PL-7, KS, OJ, EJ, ZO, Ha and MDA-5) and myositis associated antibodies 
in those with muscle complaints, unexplained elevated CK or clinical signs such as mechanic hands.  
Secondly, given the recognized association between MDS and ILD and autoimmune conditions, the 
presence of an unexplained cytopaenia should prompt referral to a haematologist.  Finally, this case 
demonstrates the complex, multi-systemic nature of CTD-ILD, requiring the input of respiratory and 
rheumatology physicians with MDT support. A specialist combined Respiratory/Rheumatology ILD-
CTD clinic, such as that run at our centre, helps to streamline this process.  
 
 
REFERENCES 
1. Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic 
syndromes. Blood 89, 2079–2088 (1997). 
 
2. Marguerie, C. et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA 
synthetase  enzymes. Q. J. Med. 77, 1019–1038 (1990). 
 
3. Labirua-Iturburu, A. et al. Anti-PL-7 (Anti-Threonyl-tRNA Synthetase) Antisynthetase 
Syndrome: Clinical Manifestations in a Series of Patients From a European Multicenter Study 
(EUMYONET) and Review of the Literature. Medicine (Baltimore). 91, (2012). 
 
4. Gunawardena, H. The Clinical Features of Myositis-Associated Autoantibodies: a Review 
Clinic Rev Allerg Immunol 52: 45 (2017) 
 
5. Cotton CV, Spencer LG, New RP, Cooper RG. The utility of comprehensive autoantibody 
testing to differentiate connective tissue disease associated and idiopathic interstitial lung 
disease subgroup cases. Rheumatology 2017;56 (8):1264-1271. 
 
6. Hervier, B. et al. Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-
PL7) antibodies. Eur. Respir. J. 37, 714 LP  – 717 (2011). 
 
7. Alexanderson H1, Lundberg IE. The role of exercise in the rehabilitation of idiopathic 
inflammatory myopathies Curr Opin Rheumatol. 2005 Mar;17(2):164-71. 
 
8. Morisset J, Johnson C, Rich E, Collard HR, Lee JS Management of Myositis-Related Interstitial 
Lung Disease. Chest. 2016 Nov;150(5):1118-1128. doi: 10.1016/j.chest.2016.04.007. Epub 
2016 Apr 19. 
 
9. Sharp, C. et al. Rituximab in autoimmune connective tissue disease–associated interstitial 
lung disease. Rheumatology 55, 1318–1324 (2016). 
 
10. Komrokji, R. S. et al. Autoimmune diseases and myelodysplastic syndromes. Am. J. Hematol. 
91, E280–3 (2016). 
 
11. Voulgarelis, M., Giannouli, S., Ritis, K. & Tzioufas, A. G. Myelodysplasia-associated 
autoimmunity: clinical and pathophysiologic concepts. Eur. J. Clin. Invest. 34, 690–700 
(2004).  
 
12. Enright, H. et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic 
syndromes: response to immunosuppressive therapy. Br. J. Haematol. 91, 403–408 (1995). 
 
13. Nanah R. et al Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients 
diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. Leuk Res. 2016 
Nov;50:112-115 
 
14. Armanios M. Syndromes of telomere shortening. Annu. Rev. Genom. Hum. Genet. 
2009;10:45–61. 
 
15. Diaz de Leon A, Cronkhite J, Katzenstein A-L A., Telomere lengths, pulmonary fibrosis and 
telomerase (TERT) mutations. PLoS One 2010; 5(5):e10680. 
 
 
 
